Navigation Links
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Date:4/29/2009

is related to edema and the growth of abnormal new blood vessels that are mediated by vascular endothelial growth factor (VEGF), we are hopeful that VEGF Trap-Eye may help address this significant unmet medical need."

About CRVO

Over 100,000 people in the United States are estimated to suffer from CRVO. CRVO is caused by obstruction of the central retinal vein that leads to a back up of blood and fluid in the retina, resulting in retinal injury and loss of vision. The retina can also become "ischemic" (starved for oxygen), resulting in the growth of new abnormal blood vessels that can cause further vision loss and more serious complications. Release of VEGF contributes to increased vascular permeability in the eye and abnormal new vessel growth. It is believed that anti-VEGF treatment may help decrease vascular permeability and edema and prevent the growth of abnormal new blood vessels in the retina in patients with CRVO.

About the Phase 3 CRVO Program

In the Phase 3 CRVO program for VEGF Trap-Eye, Regeneron and Bayer HealthCare will conduct two identical multinational clinical studies: COPERNICUS (COntrolled Phase 3 Evaluation of Repeated iNtravitreal administration of VEGF Trap-Eye In Central retinal vein occlusion: Utility and Safety) will be led by Regeneron and GALILEO (General Assessment Limiting InfiLtration of Exudates in central retinal vein Occlusion with VEGF Trap-Eye) will be led by Bayer HealthCare. Enrollment will be initiated later in 2009.

Patients in both studies will receive 6 monthly intravitreal injections of either VEGF Trap-Eye at a dose of 2 milligrams (mg) or sham control injections. The primary endpoint of both studies is improvement in visual acuity versus baseline after 6 mon
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.; Bayer HealthCare AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
2. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
3. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
4. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
5. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
6. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
7. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
8. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
9. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
10. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
11. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  Mark Riccio, director of Cornell University,s ... using the online crowd-funding platform Kickstarter to bring ... researchers and would-be superheros everywhere: "for FREE." Riccio,s ... do if you had Superman,s X-ray vision?" The ... everywhere, from elementary through high school students, academic ...
(Date:8/22/2014)... , August 22, 2014 ... TVs Today Lincor announced general availability of ... solution that delivers a range of education, entertainment and ...      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , " ... point of care patient engagement to bedside smart devices, ...
(Date:8/22/2014)... COLORADO SPRINGS, Colo. , Aug. 22, 2014 ... Company specializing in cannabis formulation-based drug development and ... of UFCM iCare,s third international medical cannabis conference ... Strasbourg, France , on October ... experts with other stakeholders, such as researchers, health ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
(Date:8/22/2014)... European Society for Medical Oncology (ESMO), the leading ... the names of three outstanding individuals receiving the ... presented to Carsten Bokemeyer, Heikki Joensuu and Peter ... Congress, 26-30 September, Madrid, Spain. , Carsten Bokemeyer ... to accelerate the transition of cancer discovery into ...
(Date:8/22/2014)... 22, 2014 Braverman Eye Center is ... Lauderdale at the most affordable fee. They are on ... their advanced Lasik treatments. LASIK is a highly successful ... Eye Center has been delivering successful LASIK solutions to ... glasses-free and contact lenses-free life with the help of ...
(Date:8/22/2014)... The report "Higher Education Market [Software Solutions, Content ... Student & Curriculum, Performance Management] - Worldwide Market ... global Higher Ed market into various sub-segments with ... The report also identifies the factors driving this ... with the adoption trends. , Browse more ...
(Date:8/22/2014)... Each year approx. 265,000 Danes are acutely admitted to ... from Aarhus University and Aarhus University Hospital now shows ... fourth patient are sent home again without receiving ... the acute hospitalisation., "Naturally, there is no need for ... that there is a serious illness. So some patients ...
(Date:8/22/2014)... a wide range of epigenetic changesalterations in DNA across ... children with Crohn,s disease (CD), reports Inflammatory Bowel ... Colitis Foundation of America (CCFA). The journal is ... of Wolters Kluwer Health . , The ... regions of the genome in children with CD, according to ...
Breaking Medicine News(10 mins):Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Higher Education Market Worth $65.83 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Many patients are discharged without a diagnosis 2Health News:Study shows epigenetic changes in children with Crohn's disease 2
... GIFT IDEA FOR THE DOG, CAT, ANIMAL LOVER ON YOUR LIST ... Betty White, Emmy-award winner and TV legend, is also one of ... more than 40 years, she has been a tremendous supporter of ... of the organization,s board of trustees and is a current trustee. ...
... TV Movie Portrayal of Tourette Syndrome , ... million people watched last Sunday night,s Hallmark Hall of Fame ... on the true story of a young man,s struggles with ... winning teacher. The national Tourette Syndrome Association, Inc. (TSA) ...
... could be part of mental exercise routine for older ... Older people who want to stay sharp should reconsider ... children and pick up a joystick themselves, a new ... playing video games has many positive benefits, ranging from ...
... in the clinic and the laboratory continue to work ... drugs. With tamoxifen,s discovery 30 years behind us, and ... studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among ... the CTRC-AACR San Antonio Breast Cancer Symposium. , ...
... of the largest studies in hormone receptor positive women ... , PHILADELPHIA, Dec. 11 New results ... (lapatinib) plus Femara(R) (letrozole) versus letrozole alone as a ... breast cancer. In the study, women diagnosed with post-menopausal, ...
... Sister Carol Keehan, DC, president and chief executive officer ... issued the following statement: , , ... nomination today of former Senate Majority Leader Tom Daschle to ... person to oversee a new White House Office of Health ...
Cached Medicine News:Health News:Betty White's Video States Support for Funding Humane Research to Help Pets and Wild Animals - Actress is 40-Year Champion of Morris Animal Foundation 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Playing Video Games May Boost Older Brains 2Health News:Playing Video Games May Boost Older Brains 3Health News:Cancer drugs in the pipeline 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7Health News:Catholic Health Association Statement on the Naming of Tom Daschle and Jeanne Lambrew to Health Leadership Positions in President-Elect Obama's Administration 2
... Renu Multiplus preservative free lubricating ... moisturize your eyes while you're ... gentle preservative free formula is ... be sensitive to preservatives and ...
... Multiplus No Rub formula is the most ... All steps in one bottle without the ... soft contact lenses and removes protein build-up ... solution that contains Hydranate, a special ingredient ...
... Sensitive Eyes saline solution ... saline solution for people ... solution for rinsing soft ... or chemical disinfection. May ...
... enzymatic cleaner is a fast-acting ... stubborn deposits in as little ... enzymatic cleaner contains an enzyme ... film on soft contact lenses ...
Medicine Products: